{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:11:10Z","timestamp":1778865070568,"version":"3.51.4"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1097\/00000441-200302000-00005","type":"journal-article","created":{"date-parts":[[2003,11,10]],"date-time":"2003-11-10T11:28:49Z","timestamp":1068463729000},"page":"75-92","source":"Crossref","is-referenced-by-count":68,"title":["New Indications for Treatment of Chronic Inflammation by TNF-\u03b1 Blockade"],"prefix":"10.1016","volume":"325","author":[{"given":"Norman M.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biff F.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas M.","family":"Reimold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/00000441-200302000-00005_bb0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00000441-200204000-00006","article-title":"Biological modifier therapy for the treatment of rheumatoid arthritis","volume":"323","author":"Jenkins","year":"2002","journal-title":"Am J Med Sci"},{"key":"10.1097\/00000441-200302000-00005_bb0015","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.1780340908","article-title":"Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis","volume":"34","author":"Chu","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0020","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J"},{"key":"10.1097\/00000441-200302000-00005_bb0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1097\/00000441-200302000-00005_bb0030","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0040","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1097\/00000441-200302000-00005_bb0045","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0050","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0055","first-page":"S78","article-title":"Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA Trial): observations at 3 years [abstract]","volume":"44","author":"Genovese","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0065","first-page":"S292","article-title":"Safety and efficacy of etanercept (Enbrel) in children with JRA less than 4 years of age [abstract]","volume":"44","author":"Rothman","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0070","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still\u2019s disease","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0075","first-page":"S118","article-title":"Successful therapy with infliximab in refractory adult onset Still\u2019s disease [Abstract]","volume":"44","author":"Aurrecoechea","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0080","first-page":"S118","article-title":"Successful treatment of a small cohort of adult onset Still disease with infliximab [abstract]","volume":"44","author":"Kraetsch","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0085","doi-asserted-by":"crossref","first-page":"13C","DOI":"10.1155\/2000\/409396","article-title":"Biology of inflammation in Crohn\u2019s disease: mechanisms of action of anti-TNF-a therapy","volume":"14","author":"Targan","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"10.1097\/00000441-200302000-00005_bb0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-3083.2000.00658.x","article-title":"Recent developments in the immunology of inflammatory bowel disease","volume":"51","author":"MacDonald","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1097\/00000441-200302000-00005_bb0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0100","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1097\/00000441-200302000-00005_bb0105","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0110","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1097\/00000441-200302000-00005_bb0115","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1097\/00000441-200302000-00005_bb0120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1084\/jem.179.3.849","article-title":"Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock","volume":"179","author":"Suitters","year":"1994","journal-title":"J Exp Med"},{"key":"10.1097\/00000441-200302000-00005_bb0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn\u2019s disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1097\/00000441-200302000-00005_bb0130","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn\u2019s disease: a randomized double-blind placebo-controlled trial","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1097\/00000441-200302000-00005_bb0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jir.1998.18.219","article-title":"Transgenic mice expressing a truncatedPeromyscus leucopusTNF-alpha gene manifest an arthritis resembling ankylosing spondylitis","volume":"18","author":"Crew","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"10.1097\/00000441-200302000-00005_bb0140","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratacos","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1097\/00000441-200302000-00005_bb0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ard.59.2.135","article-title":"Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging","volume":"59","author":"Bollow","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/00000441-200302000-00005_bb0150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00002281-199607000-00003","article-title":"The sacroiliac joint in the spondyloarthropathies","volume":"8","author":"Braun","year":"1996","journal-title":"Curr Opin Rheumatol"},{"key":"10.1097\/00000441-200302000-00005_bb0155","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/rheumatology\/36.1.38","article-title":"Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies","volume":"36","author":"Canete","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1097\/00000441-200302000-00005_bb0165","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.1780391013","article-title":"Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy","volume":"39","author":"Grom","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00054725-199905000-00008","article-title":"Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety","volume":"5","author":"Sandborn","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"10.1097\/00000441-200302000-00005_bb0175","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H","article-title":"Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study","volume":"44","author":"Marzo-Ortega","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0180","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1097\/00000441-200302000-00005_bb0185","first-page":"S153","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) versus placebo in active spondyloarthropathy [abstract]","volume":"44","author":"Van den Bosch","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0190","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0195","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short- term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0200","first-page":"S90","article-title":"A randomized, double-blind, placebo-controlled trial of etanercept (Enbrel) in the treatment of ankylosing spondylitis [abstract]","volume":"44","author":"Gorman","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0205","first-page":"S91","article-title":"An open-label trial of etanercept in the treatment of ankylosing spondylitis [abstract]","volume":"44","author":"Gorman","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0210","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1097\/00000441-200302000-00005_bb0215","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1097\/00000441-200302000-00005_bb0220","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1097\/00000441-200302000-00005_bb0225","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1097\/00000441-200302000-00005_bb0230","first-page":"S383","article-title":"Infliximab monotherapy in the treatment of plaque-type psoriasis [abstract]","volume":"44","author":"Gottlieb","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0235","first-page":"S121","article-title":"Treatment of psoriatic arthritis with infliximab in a small office-based rheumatology practice [abstract]","volume":"44","author":"Bolce","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0240","first-page":"S121","article-title":"Emerging role of (Remicade) in psoriatic arthritis patients resistant to disease-modifying antirheumatic drugs: case studies [abstract]","volume":"44","author":"Bray","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0245","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2133.2001.04089.x","article-title":"Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate","volume":"144","author":"Ogilvie","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1097\/00000441-200302000-00005_bb0250","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1097\/00000441-200302000-00005_bb0255","first-page":"S90","article-title":"Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial [abstract]","volume":"44","author":"Mease","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0260","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":"Etanercept therapy in children with treatment-resistant uveitis","volume":"44","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0265","first-page":"S292","article-title":"Infliximab treatment in the refractory chronic uveitis of juvenile idiopathic arthritis (JIA) [abstract]","volume":"44","author":"Honkanen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0270","first-page":"S123","article-title":"Anti-TNF\u03b1 therapy with infliximab in the treatment of HLA B27 associated acute anterior uveitis [abstract]","volume":"44","author":"El-Shabrawi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0275","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0280","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1097\/00000441-200302000-00005_bb0285","first-page":"S90","article-title":"Treatment of refractory posterior uveitis with anti-TNF-alpha (infliximab) [abstract]","volume":"44","author":"Banares","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0290","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/gast.2001.22556","article-title":"Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet\u2019s disease: a case report","volume":"120","author":"Hassard","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1097\/00000441-200302000-00005_bb0295","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","article-title":"Treatment of recalcitrant orogenital ulceration of Behcet\u2019s syndrome with infliximab","volume":"40","author":"Robertson","year":"2001","journal-title":"Rheumatology Oxford"},{"key":"10.1097\/00000441-200302000-00005_bb0300","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard.61.3.283-a","article-title":"Remission of Behcet\u2019s syndrome with TNFalpha blocking treatment","volume":"61","author":"Rozenbaum","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/00000441-200302000-00005_bb0305","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0925-5710(96)00455-0","article-title":"Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines","volume":"63","author":"Raza","year":"1996","journal-title":"Int J Hematol"},{"key":"10.1097\/00000441-200302000-00005_bb0310","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood.V88.7.2640.bloodjournal8872640","article-title":"Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes","volume":"88","author":"Mundle","year":"1996","journal-title":"Blood"},{"key":"10.1097\/00000441-200302000-00005_bb0315","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0145-2126(96)00008-2","article-title":"Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes","volume":"20","author":"Shetty","year":"1996","journal-title":"Leuk Res"},{"key":"10.1097\/00000441-200302000-00005_bb0320","series-title":"Acute leukemias VII: experimental approaches and novel therapies","first-page":"42","article-title":"Pilot study of pentoxifylline and Ciprofloxacin with or without dexamethasone produces encouraging results in myelodysplastic syndromes","author":"Raza","year":"1998"},{"key":"10.1097\/00000441-200302000-00005_bb0325","first-page":"305a","article-title":"Encouraging response to amifostine, pentoxifylline, ciprofloxacin, dexamethasone (A-PCD) + topotecan in patients with myelodysplastic syndromes (MDS) [abstract]","volume":"94","author":"Raza","year":"1999","journal-title":"Blood"},{"key":"10.1097\/00000441-200302000-00005_bb0330","first-page":"171b","article-title":"Biologic and clinical response to recombinant human soluble tumor necrosis factor receptor (Enbrel) in patients with myelodysplastic syndromes (MDS) [abstract]","volume":"94","author":"Raza","year":"1999","journal-title":"Blood"},{"key":"10.1097\/00000441-200302000-00005_bb0335","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-2141.2002.03381.x","article-title":"A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome","volume":"117","author":"Maciejewski","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1097\/00000441-200302000-00005_bb0340","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/sj.leu.2402356","article-title":"Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study","volume":"16","author":"Deeg","year":"2002","journal-title":"Leukemia"},{"key":"10.1097\/00000441-200302000-00005_bb0345","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1046\/j.1365-2141.2002.03279.x","article-title":"Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes","volume":"116","author":"Stasi","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1097\/00000441-200302000-00005_bb0350","first-page":"99","article-title":"TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD","volume":"15","author":"Remberger","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1097\/00000441-200302000-00005_bb0355","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00007890-199511150-00011","article-title":"Elevated inflammatory cytokine levels in bone marrow graft rejection","volume":"60","author":"Nagler","year":"1995","journal-title":"Transplantation"},{"key":"10.1097\/00000441-200302000-00005_bb0360","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V75.4.1024.1024","article-title":"Treatment of moderate\/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome","volume":"75","author":"Weisdorf","year":"1990","journal-title":"Blood"},{"key":"10.1097\/00000441-200302000-00005_bb0365","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V79.12.3362.bloodjournal79123362","article-title":"Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease","volume":"79","author":"Herve","year":"1992","journal-title":"Blood"},{"key":"10.1097\/00000441-200302000-00005_bb0370","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00001622-200011000-00011","article-title":"Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation","volume":"12","author":"Couriel","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.1097\/00000441-200302000-00005_bb0375","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/00007890-200202270-00035","article-title":"Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease","volume":"73","author":"Chiang","year":"2002","journal-title":"Transplantation"},{"key":"10.1097\/00000441-200302000-00005_bb0380","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/sj.bmt.1702638","article-title":"Etanercept in graft-versus-host disease [letter]","volume":"26","author":"Andolina","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1097\/00000441-200302000-00005_bb0385","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.270.5234.286","article-title":"Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis","volume":"270","author":"Auphan","year":"1995","journal-title":"Science"},{"key":"10.1097\/00000441-200302000-00005_bb0390","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1126\/science.2119054","article-title":"Transcription factor interactions: selectors of positive or negative regulation from a single DNA element","volume":"249","author":"Diamond","year":"1990","journal-title":"Science"},{"key":"10.1097\/00000441-200302000-00005_bb0395","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1073\/pnas.91.2.752","article-title":"Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor","volume":"91","author":"Ray","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/00000441-200302000-00005_bb0400","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.270.5234.283","article-title":"Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids","volume":"270","author":"Scheinman","year":"1995","journal-title":"Science"},{"key":"10.1097\/00000441-200302000-00005_bb0405","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/PL00012387","article-title":"Targets of glucocorticoid action on TNF-alpha release by macrophages","volume":"50","author":"Joyce","year":"2001","journal-title":"Inflamm Res"},{"key":"10.1097\/00000441-200302000-00005_bb0410","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM199505183322008","article-title":"The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation","volume":"332","author":"Chrousos","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0415","series-title":"Tumor necrosis factor structure, mechanism of action, role in disease and therapy","first-page":"187","author":"Galanos","year":"1990"},{"key":"10.1097\/00000441-200302000-00005_bb0420","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/00003246-199508000-00019","article-title":"Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature","volume":"23","author":"Cronin","year":"1995","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0425","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00003246-199804000-00010","article-title":"Reversal of late septic shock with supraphysiologic doses of hydrocortisone","volume":"26","author":"Bollaert","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0430","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/00003246-199904000-00025","article-title":"Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study","volume":"27","author":"Briegel","year":"1999","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0435","doi-asserted-by":"crossref","first-page":"A33","DOI":"10.1097\/00003246-199901001-00022","article-title":"Hydrocortisone reverses refractory septic shock","volume":"27","author":"Chawla","year":"1999","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0440","first-page":"S195","article-title":"Effects of hydrocortisone on the immune response in patients with septic shock: results from a double-blind cross-over study","volume":"1","author":"Key","year":"1999","journal-title":"J Anaesth Intens Care"},{"key":"10.1097\/00000441-200302000-00005_bb0445","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/00003246-200107001-00036","article-title":"Corticosteroids for septic shock","volume":"29","author":"Annane","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0450","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1179\/joc.1999.11.6.541","article-title":"New rationale for glucocorticoid treatment in septic shock","volume":"11","author":"Meduri","year":"1999","journal-title":"J Chemother"},{"key":"10.1097\/00000441-200302000-00005_bb0455","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/BF00180547","article-title":"Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group","volume":"72","author":"Briegel","year":"1994","journal-title":"Clin Investig"},{"key":"10.1097\/00000441-200302000-00005_bb0460","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.1995.03520360048038","article-title":"Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group","volume":"273","author":"Abraham","year":"1995","journal-title":"JAMA"},{"key":"10.1097\/00000441-200302000-00005_bb0465","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","article-title":"Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group","volume":"351","author":"Abraham","year":"1998","journal-title":"Lancet"},{"key":"10.1097\/00000441-200302000-00005_bb0470","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00003246-199609000-00002","article-title":"INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group","volume":"24","author":"Cohen","year":"1996","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0475","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00003246-199605000-00003","article-title":"Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose- ranging study","volume":"24","author":"Reinhart","year":"1996","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0480","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","article-title":"Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis","volume":"41","author":"Cid","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0485","first-page":"A200","article-title":"Treatment with afelimomab in patients with severe sepsis is associated with improved ICU-free days [abstract]","volume":"28","author":"Panacek","year":"2000","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0490","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1097\/00003246-200107001-00037","article-title":"Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned","volume":"29","author":"Reinhart","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0495","first-page":"S283","article-title":"Biologic effect of afelimomab on serum IL-6 and TNF\u03b1 concentrations [abstract]","volume":"26","author":"Panacek","year":"2000","journal-title":"Intensive Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0500","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group","volume":"334","author":"Fisher","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0505","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.1997.03540430043031","article-title":"p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group","volume":"277","author":"Abraham","year":"1997","journal-title":"JAMA"},{"key":"10.1097\/00000441-200302000-00005_bb0510","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1568008013341794","article-title":"Pathogenic aspects of sepsis and possible targets for adjunctive therapy","volume":"1","author":"Rigato","year":"2001","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1097\/00000441-200302000-00005_bb0515","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1097\/00003246-199909000-00018","article-title":"Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis","volume":"27","author":"Oberhoffer","year":"1999","journal-title":"Crit Care Med"},{"key":"10.1097\/00000441-200302000-00005_bb0520","first-page":"S81","article-title":"Long-term follow-up of patients treated with Remicade (infliximab) in clinical trials [abstract]","volume":"44","author":"Kavanaugh","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0525","first-page":"S77","article-title":"Global safety and efficacy of up to five years of etanercept (Enbrel) therapy [abstract]","volume":"44","author":"Klareskog","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0530","first-page":"S78","article-title":"Etanercept (Enbrel) in addition to methotrexate (MTX) in rheumatoid arthritis (RA): long-term observations [abstract]","volume":"44","author":"Kremer","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0535","first-page":"S78","article-title":"Infection reports wih etanercept (Enbrel) therapy [abstract]","volume":"44","author":"Wallis","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0540","first-page":"S173","article-title":"Infections associated with etanercept treatment of rheumatoid arthritis: 2 years of experience in the \u201creal-world\u201d [abstract]","volume":"44","author":"Belostocki","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0545","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200302000-00005_bb0550","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.4049\/jimmunol.162.6.3504","article-title":"Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosolMycobacterium tuberculosisinfection, which is not compensated for by lymphotoxin","volume":"162","author":"Bean","year":"1999","journal-title":"J Immunol"},{"key":"10.1097\/00000441-200302000-00005_bb0555","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect Immun"},{"key":"10.1097\/00000441-200302000-00005_bb0560","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response againstMycobacterium tuberculosisin mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"10.1097\/00000441-200302000-00005_bb0565","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.4049\/jimmunol.157.11.5022","article-title":"Corynebacterium parvum- andMycobacterium bovisbacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF- RI) knockout mice and by treatment with soluble TNF-RI","volume":"157","author":"Senaldi","year":"1996","journal-title":"J Immunol"},{"key":"10.1097\/00000441-200302000-00005_bb0570","first-page":"S105","article-title":"Tuberculosis infection in patients with rheumatoid arthritis [abstract]","volume":"44","author":"Wolfe","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0575","first-page":"S78","article-title":"Tuberculosis experience with etanercept (Enbrel) therapy [abstract]","volume":"44","author":"Wallis","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0580","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","author":"Anonymous","year":"1999","journal-title":"Neurology"},{"key":"10.1097\/00000441-200302000-00005_bb0585","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/00000441-200302000-00005_bb0590","first-page":"S90","article-title":"TNF\u03b1 blockade with infliximab in patients with active spondyloarthropathy: follow-up of one year maintenance regimen","volume":"44","author":"Kruithof","year":"2001","journal-title":"Arthritis Rheum"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915343251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915343251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T09:13:14Z","timestamp":1704964394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915343251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S0002962915343251"],"URL":"https:\/\/doi.org\/10.1097\/00000441-200302000-00005","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}